| Literature DB >> 32134744 |
Sean J Judge1, Cordelia Dunai2, Ethan G Aguilar2, Sarah C Vick3, Ian R Sturgill2, Lam T Khuat2, Kevin M Stoffel2, Jonathan Van Dyke4, Dan L Longo5, Morgan A Darrow6, Stephen K Anderson7, Bruce R Blazar8,9, Arta M Monjazeb10, Jonathan S Serody11,12, Robert J Canter1, William J Murphy2,13.
Abstract
PD-1 expression is a hallmark of both early antigen-specific T cell activation and later chronic stimulation, suggesting key roles in both naive T cell priming and memory T cell responses. Although significant similarities exist between T cells and NK cells, there are critical differences in their biology and functions reflecting their respective adaptive and innate immune effector functions. Expression of PD-1 on NK cells is controversial despite rapid incorporation into clinical cancer trials. Our objective was to stringently and comprehensively assess expression of PD-1 on both mouse and human NK cells under multiple conditions and using a variety of readouts. We evaluated NK cells from primary human tumor samples, after ex vivo culturing, and from multiple mouse tumor and viral models using flow cytometry, quantitative reverse-transcriptase PCR (qRT-PCR), and RNA-Seq for PD-1 expression. We demonstrate that, under multiple conditions, human and mouse NK cells consistently lack PD-1 expression despite the marked upregulation of other activation/regulatory markers, such as TIGIT. This was in marked contrast to T cells, which were far more prominent within all tumors and expressed PD-1. These data have important implications when attempting to discern NK from T cell effects and to determine whether PD-1 targeting can be expected to have direct effects on NK cell functions.Entities:
Keywords: Immunology; Immunotherapy; NK cells
Mesh:
Substances:
Year: 2020 PMID: 32134744 PMCID: PMC7260004 DOI: 10.1172/JCI133353
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808